Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...

A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...

Eli Lilly has filed lawsuits ... solutions for individual patient needs. The legal action also questions the safety of the compounded drugs and challenges whether the defendants are violating ...

Lilly sues four telehealth firms for unauthorized compounding of Mounjaro and Zepbound. 2. GLP 1 drugs remain in high demand ...

Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo ...

Eli Lilly has raised its revenue guidance for ... "While weekly prescription volume was volatile in the first half of the year due to challenges fulfilling high demand, our progress on supply ...

He said that is "likely to challenge growth in the end of the decade," especially as Eli Lilly's own obesity pill impresses investors and inches closer to entering the market. Unlike oral ...

We are maintaining Eli Lilly’s Uncertainty Rating ... encounters considerable regulatory and legal risks, including product approvals, patent challenges, and liability lawsuits.